Patients with atrophy (n=47) |
|
Time to development of atrophy (mos), median (IQR) |
29.6 (17.7 - 43.4) |
Vascularized PED → Atrophy SRHRM/SR fibrosis → Atrophy Drusen → Atrophy a.Reticular pseudodrusen, n/n (%) b.Typical drusen, n/n (%) |
25 15 13 3/13 (23.1) 10/13 (76.9) |
Patients who developed atrophy from: Single reason Multiple reasons a.Vascularized PED → Atrophy and Drusen → Atrophy, n/n (%) b.SRHRM/SR fibrosis → Atrophy and Drusen → Atrophy, n/n (%) |
41 (87.2) 6 (12.8) 5/6 (83.3) 1/6 (16.7) |
Decreased CNV activity after collapse of vascularized PED, n/n (%) |
15/25 (60.0) |
mos: months; VA: visual acuity; PED: pigment epithelial detachment; NV: neovascular; CNV: choroidal neovascularization; SR: subretinal; HRM: hyperreflective material |
|
Patients with atrophy (n=47) |
Baseline Demographic Characteristics |
|
Age (yrs), mean±SEM |
80.8±1.0 |
Females, n (%) |
34 (72.3) |
Race, n (%) White |
47 (100) |
Follow-up duration (mos), median (IQR) |
57.5 (47.4 - 73.4) |
Baseline VA (Snellen), n (%) 20/50 or better 20/63 - 20/160 20/200 or worse |
28 (59.6) 18 (38.3) 1 (2.1) |
Baseline Anatomic Characteristics |
|
Fellow Eye, n (%) Atrophy SR Fibrosis |
19 (40.4) 15 (31.9) |
Study Eye, n (%) Intraretinal cysts Subretinal fluid Reticular pseudodrusen Intraretinal pigment migration SRHRM |
38 (80.9) 32 (68.1) 21 (44.7) 35 (74.5) 24 (51.1) |
VA: visual acuity; SEM: standard error of mean; mos: months; IQR: interquartile range; SR: subretinal; SRHRM: subretinal hyperreflective material |
Patients with atrophy (n=47) |
|
Follow-up duration (mos), median (IQR) |
57.5 (47.4 - 73.4) |
Baseline VA (letters), median (IQR) |
65 (60 - 70) |
Baseline VA, n (%) 20/50 or better 20/63 - 20/160 20/200 or worse |
28 (59.6) 18 (38.3) 1 (2.1) |
Final VA (letters), median (IQR) |
55 (35 - 70) |
Final VA, n (%) 20/50 or better 20/63 - 20/160 20/200 or worse |
17 (36.2) 16 (34.0) 14 (29.8) |
Change in VA, n (%) Gain of ≥3 lines Change of <3 lines Loss of ≥3 lines |
4 (8.5) 21 (44.7) 22 (46.8) |
Peak VA (letters), median (IQR) |
75 (70 - 80) |
Peak VA, n (%) 20/50 or better 20/63 - 20/160 20/200 or worse |
43 (91.5) 4 (8.5) 0 (0) |
Change in VA among patients with foveal atrophy, n/n (%) Gain of ≥3 lines Change of <3 lines Loss of ≥3 lines
Change in VA among patients with non-foveal atrophy, n/n (%) Gain of ≥3 lines Change of <3 lines Loss of ≥3 lines |
n=21 (44.7%) 1/21 (4.8)* 7/21 (33.3) 13/21 (61.9)
n=26 (55.3%) 3/26 (11.5) 14/26 (53.9) 9/26 (34.6)** |
Recent follow-up visit with peak VA (mos), median (IQR) |
24 (14 - 39) |
Total number of recurrences, median (IQR) |
15 (8 - 26) |
Number of Anti-VEGF injections, median (IQR)
|
20 (10 - 29) |
Frequency of Anti-VEGF injections, n (%) Every 4-6 weeks Every >6-12 weeks*** PRN with long intervals without treatment |
7 (14.9) 15 (31.9) 25 (53.2) |
Continuous variables are described as median (IQR).
VA: visual acuity; SEM: standard error of mean; mos: months; PRN: pro re nata
*Patient who gained 3 lines of visual acuity after undergoing cataract surgery. **Five of the nine patients with non-foveal atrophy who had loss of VA had subfoveal fibrosis, rest of the four patients had loss of VA from visually significant cataract, persistent intraretinal cystoid spaces involving the fovea despite treatment with anti-VEGF injections, combination of persistent intraretinal cystoid spaces involving the parafoveal region despite treatment with anti-VEGF injections and corneal edema from anterior basement membrane dystrophy, and subretinal hemorrhage involving the fovea. |
Patients with atrophy (n=47) |
|
Time to development of atrophy (mos), median (IQR) |
29.6 (17.7 - 43.4) |
Vascularized PED → Atrophy SRHRM/SR fibrosis → Atrophy Drusen → Atrophy a.Reticular pseudodrusen, n/n (%) b.Typical drusen, n/n (%) |
25 15 13 3/13 (23.1) 10/13 (76.9) |
Patients who developed atrophy from: Single reason Multiple reasons a.Vascularized PED → Atrophy and Drusen → Atrophy, n/n (%) b.SRHRM/SR fibrosis → Atrophy and Drusen → Atrophy, n/n (%) |
41 (87.2) 6 (12.8) 5/6 (83.3) 1/6 (16.7) |
Decreased CNV activity after collapse of vascularized PED, n/n (%) |
15/25 (60.0) |
mos: months; VA: visual acuity; PED: pigment epithelial detachment; NV: neovascular; CNV: choroidal neovascularization; SR: subretinal; HRM: hyperreflective material |
|
Patients with atrophy (n=47) |
Baseline Demographic Characteristics |
|
Age (yrs), mean±SEM |
80.8±1.0 |
Females, n (%) |
34 (72.3) |
Race, n (%) White |
47 (100) |
Follow-up duration (mos), median (IQR) |
57.5 (47.4 - 73.4) |
Baseline VA (Snellen), n (%) 20/50 or better 20/63 - 20/160 20/200 or worse |
28 (59.6) 18 (38.3) 1 (2.1) |
Baseline Anatomic Characteristics |
|
Fellow Eye, n (%) Atrophy SR Fibrosis |
19 (40.4) 15 (31.9) |
Study Eye, n (%) Intraretinal cysts Subretinal fluid Reticular pseudodrusen Intraretinal pigment migration SRHRM |
38 (80.9) 32 (68.1) 21 (44.7) 35 (74.5) 24 (51.1) |
VA: visual acuity; SEM: standard error of mean; mos: months; IQR: interquartile range; SR: subretinal; SRHRM: subretinal hyperreflective material |
Patients with atrophy (n=47) |
|
Follow-up duration (mos), median (IQR) |
57.5 (47.4 - 73.4) |
Baseline VA (letters), median (IQR) |
65 (60 - 70) |
Baseline VA, n (%) 20/50 or better 20/63 - 20/160 20/200 or worse |
28 (59.6) 18 (38.3) 1 (2.1) |
Final VA (letters), median (IQR) |
55 (35 - 70) |
Final VA, n (%) 20/50 or better 20/63 - 20/160 20/200 or worse |
17 (36.2) 16 (34.0) 14 (29.8) |
Change in VA, n (%) Gain of ≥3 lines Change of <3 lines Loss of ≥3 lines |
4 (8.5) 21 (44.7) 22 (46.8) |
Peak VA (letters), median (IQR) |
75 (70 - 80) |
Peak VA, n (%) 20/50 or better 20/63 - 20/160 20/200 or worse |
43 (91.5) 4 (8.5) 0 (0) |
Change in VA among patients with foveal atrophy, n/n (%) Gain of ≥3 lines Change of <3 lines Loss of ≥3 lines
Change in VA among patients with non-foveal atrophy, n/n (%) Gain of ≥3 lines Change of <3 lines Loss of ≥3 lines |
n=21 (44.7%) 1/21 (4.8)* 7/21 (33.3) 13/21 (61.9)
n=26 (55.3%) 3/26 (11.5) 14/26 (53.9) 9/26 (34.6)** |
Recent follow-up visit with peak VA (mos), median (IQR) |
24 (14 - 39) |
Total number of recurrences, median (IQR) |
15 (8 - 26) |
Number of Anti-VEGF injections, median (IQR)
|
20 (10 - 29) |
Frequency of Anti-VEGF injections, n (%) Every 4-6 weeks Every >6-12 weeks*** PRN with long intervals without treatment |
7 (14.9) 15 (31.9) 25 (53.2) |
Continuous variables are described as median (IQR).
VA: visual acuity; SEM: standard error of mean; mos: months; PRN: pro re nata
*Patient who gained 3 lines of visual acuity after undergoing cataract surgery. **Five of the nine patients with non-foveal atrophy who had loss of VA had subfoveal fibrosis, rest of the four patients had loss of VA from visually significant cataract, persistent intraretinal cystoid spaces involving the fovea despite treatment with anti-VEGF injections, combination of persistent intraretinal cystoid spaces involving the parafoveal region despite treatment with anti-VEGF injections and corneal edema from anterior basement membrane dystrophy, and subretinal hemorrhage involving the fovea. |
Patients with atrophy (n=47) |
|
Follow-up duration (mos), median (IQR) |
57.5 (47.4 - 73.4) |
Baseline VA (letters), median (IQR) |
65 (60 - 70) |
Baseline VA, n (%) 20/50 or better 20/63 - 20/160 20/200 or worse |
28 (59.6) 18 (38.3) 1 (2.1) |
Final VA (letters), median (IQR) |
55 (35 - 70) |
Final VA, n (%) 20/50 or better 20/63 - 20/160 20/200 or worse |
17 (36.2) 16 (34.0) 14 (29.8) |
Change in VA, n (%) Gain of ≥3 lines Change of <3 lines Loss of ≥3 lines |
4 (8.5) 21 (44.7) 22 (46.8) |
Peak VA (letters), median (IQR) |
75 (70 - 80) |
Peak VA, n (%) 20/50 or better 20/63 - 20/160 20/200 or worse |
43 (91.5) 4 (8.5) 0 (0) |
Change in VA among patients with foveal atrophy, n/n (%) Gain of ≥3 lines Change of <3 lines Loss of ≥3 lines
Change in VA among patients with non-foveal atrophy, n/n (%) Gain of ≥3 lines Change of <3 lines Loss of ≥3 lines |
n=21 (44.7%) 1/21 (4.8)* 7/21 (33.3) 13/21 (61.9)
n=26 (55.3%) 3/26 (11.5) 14/26 (53.9) 9/26 (34.6)** |
Recent follow-up visit with peak VA (mos), median (IQR) |
24 (14 - 39) |
Total number of recurrences, median (IQR) |
15 (8 - 26) |
Number of Anti-VEGF injections, median (IQR)
|
20 (10 - 29) |
Frequency of Anti-VEGF injections, n (%) Every 4-6 weeks Every >6-12 weeks*** PRN with long intervals without treatment |
7 (14.9) 15 (31.9) 25 (53.2) |
Continuous variables are described as median (IQR).
VA: visual acuity; SEM: standard error of mean; mos: months; PRN: pro re nata
*Patient who gained 3 lines of visual acuity after undergoing cataract surgery. **Five of the nine patients with non-foveal atrophy who had loss of VA had subfoveal fibrosis, rest of the four patients had loss of VA from visually significant cataract, persistent intraretinal cystoid spaces involving the fovea despite treatment with anti-VEGF injections, combination of persistent intraretinal cystoid spaces involving the parafoveal region despite treatment with anti-VEGF injections and corneal edema from anterior basement membrane dystrophy, and subretinal hemorrhage involving the fovea. |